-
公开(公告)号:US20250130244A1
公开(公告)日:2025-04-24
申请号:US18999357
申请日:2024-12-23
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Aljoscha Michael Flohr , Aikaterini Georgopoulou , Rym Guennoun , Martin Hund , Martin Klammer
IPC: G01N33/68
Abstract: The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.
-
公开(公告)号:US20250116675A1
公开(公告)日:2025-04-10
申请号:US18798760
申请日:2024-08-08
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Martin Hund , Maria Schoedl
Abstract: The present invention concerns the field of diagnostic assays for prenatal diagnosis of preeclampsia. In particular, it relates to a method for diagnosing whether a pregnant subject is not at risk for preeclampsia within a short window of time comprising a) determining the amount of at least one angiogenesis biomarker selected from the group consisting of sFlt-1, Endoglin and PlGF in a sample of said subject, and b) comparing the amount with a reference, whereby a subject being not at risk for developing preeclampsia within a short period of time is diagnosed if the amount is identical or decreased compared to the reference in the cases of sFlt-1 and Endoglin and identical or increased in the case of PlGF, wherein said reference allows for making the diagnosis with a negative predictive value of at least about 98%. Further contemplates are devices and kits for carrying out said method.
-
公开(公告)号:US20250037861A1
公开(公告)日:2025-01-30
申请号:US18696634
申请日:2021-11-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Yi YAO , Wei Bin XING , Xiao Jun TAO , Jing QIAN , Qi ZHOU , Chenxi ZHANG , Yin QIAN
Abstract: A computer-implemented method is provided that includes transmitting, by a master node to a plurality of computing nodes, definition information about an initial medical validation model (410): performing, by the master node, a federated learning process together with the plurality of computing nodes (420), to jointly train the initial medical validation model using respective processed local training datasets available at the plurality of computing nodes, the respective local training datasets being processed by the plurality of computing nodes based on the definition information; and determining, by the master node, a final medical validation model based on a result of the federated learning process (430). Through the solution, by means of federated learning, it addresses the data security and privacy concerns from local sites owning.
-
公开(公告)号:US20250035629A1
公开(公告)日:2025-01-30
申请号:US18696730
申请日:2022-09-28
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Felix Gruenewald , Victor Johann Raul Jeger , Martin Klammer , Philipp Schuetz , Maria von Holtey , Stephen Weber , Heike Wegmeyer , Ursula-Henrike Wienhues-Thelen
IPC: G01N33/573 , G01N33/68
Abstract: The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being MR-proADM, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: sFlt-1, GDF15 and ESM1, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being MR-proADM and a second biomarker selected from the group consisting of: sFlt-1, GDF15 and ESM1, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
-
公开(公告)号:USD1057393S1
公开(公告)日:2025-01-14
申请号:US29841718
申请日:2022-06-08
Applicant: Roche Diagnostics Operations, Inc.
Designer: Peter Arnold , Carolin Frontzek , Sofia Elisabeth Galbraith , Roman Gebhard
-
公开(公告)号:US12196772B2
公开(公告)日:2025-01-14
申请号:US17008778
申请日:2020-09-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Riccardo Leone Benedetti , Reto Huesser , Goran Savatic , Norbert Schmitt
Abstract: A method to localize a carrier on a laboratory transport system is presented. The laboratory transport system comprises a carrier associated with an identity, a multi-lane transport module, and a control unit. The carrier comprises a signal transmitter configured to transmit a signal comprising information about the identity. The multi-lane transport module comprises a transport surface comprising a first and a second transport lane as well as a first signal receiver and a second signal receiver each configured to receive the transmitted signal. Based on received signal strengths, the control unit localizes the carrier on one of the transport lanes of the multi-lane transport module.
-
公开(公告)号:US20240426765A1
公开(公告)日:2024-12-26
申请号:US18755464
申请日:2024-06-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Juergen Hildenbrand , Alexander Kramlich , Michael Lambertson
IPC: G01N21/94
Abstract: An in-vitro diagnostic (IVD) analyzer 200 comprising an optical detection unit 217 comprising a cuvette 214 for the optical measurement of a biological sample 2, 2′ is herein disclosed. The IVD analyzer 200 further comprises a piezo actuator 218 arranged on one side of the cuvette 214 configured to transmit ultrasonic waves 254, 254′ through the cuvette 214, a piezo receiver 218′ arranged on the opposite side of the cuvette 214 configured to receive ultrasonic waves 255, 255′, 255″ transmitted through the cuvette 214 and a controller 250 configured to operate according to either a lysis operating mode (L) or an air-detection operating mode (AD). According to the lysis operating mode (L) the piezo actuator 218 is configured to transmit ultrasonic waves 254′ through the cuvette 214 for disrupting cellular particles contained in the biological sample 2. According to the air-detection operating mode (AD) the piezo actuator 218 is configured to transmit ultrasonic waves 254 through the cuvette 214 and the controller 250 is configured to correlate changes in amplitude and/or shifts of phase of the ultrasonic waves 255, 255′, 255″ received by the piezo receiver 218′ relative to reference values with an eventual presence and quantity of air 3 in the cuvette 214, in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air 3. A respective automated method of operating the in-vitro diagnostic analyzer 200 in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air is herein also disclosed.
-
公开(公告)号:US20240409436A1
公开(公告)日:2024-12-12
申请号:US18810797
申请日:2024-08-21
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Carlos Munoz , Hans Zahn
IPC: C02F1/00 , C02F103/00
Abstract: A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50% of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
-
公开(公告)号:US20240406146A1
公开(公告)日:2024-12-05
申请号:US18421536
申请日:2024-01-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Domenico de Luca
IPC: H04L9/40
Abstract: A healthcare data system. The system comprises a data protection entity configured to: sign at least a portion of a routing header of a data packet with a private key held by the data protection entity, the data packet including a payload and a routing header, the payload including healthcare data and the routing header indicating an intended consumer of the data packet; and transmit the data packet on towards the intended consumer. The healthcare data system further comprises one or more data receivers, each configured to: receive the data packet; and verify the signed routing header.
-
公开(公告)号:US12140601B2
公开(公告)日:2024-11-12
申请号:US16714865
申请日:2019-12-16
Applicant: Roche Diagnostics Operations, Inc.
Inventor: Juliane Drobnik , Mirko Klingauf , Regula Krieg
Abstract: A computer-implemented method of automatically managing calibration of an in-vitro diagnostic system is provided comprising determining a lot calibration time period in which a lot calibration is applicable to reagent containers of the same lot, having a predefined time length starting from the time when the lot calibration becomes available, upon making a reagent container of the lot available to the system, determining whether a lot calibration that has not exceeded the lot calibration time period is available and linking the reagent container to the available lot calibration or most recent available lot calibration if more than one lot calibration is available, wherein if a new lot calibration for the same lot becomes available the method comprises replacing the existing link to the previous lot calibration with a link to the new lot calibration.
-
-
-
-
-
-
-
-
-